Английская Википедия:Aripiprazole/sertraline

Материал из Онлайн справочника
Версия от 15:16, 2 февраля 2024; EducationBot (обсуждение | вклад) (Новая страница: «{{Английская Википедия/Панель перехода}} {{Short description|Medication under development by Otsuka Pharmaceutical}} {{Drugbox | image = | width = | caption = <!--Combo data--> | type = combo | drug_name = | component1 = Aripiprazole | class1 = Atypical antipsychotic | component2 = Sertraline | class2 = Selective serotonin reuptake inhibitor <!-- Clinical data --> | tradename = | Drugs.com = | MedlinePlus = | pr...»)
(разн.) ← Предыдущая версия | Текущая версия (разн.) | Следующая версия → (разн.)
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Drugbox

Aripiprazole/sertraline (developmental code name ASC-01) is a combination formulation of aripiprazole (Abilify), an atypical antipsychotic, and sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), which was under development by Otsuka Pharmaceutical for the treatment of major depressive disorder (MDD).[1] It combines serotonin reuptake inhibition from sertraline and modulation of dopamine and serotonin receptors from aripiprazole.[1][2] In July 2017, it was in preregistration in Japan for the treatment of MDD.[1] However, in September 2018, the regulatory submission in Japan for MDD was withdrawn.[3]

See also

References

Шаблон:Reflist


Шаблон:Antidepressants Шаблон:Dopamine receptor modulators Шаблон:Monoamine reuptake and release modulators Шаблон:Serotonin receptor modulators


Шаблон:Nervous-system-drug-stub